Does her2/neu-positive disease increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy , mastectomy , and radiotherapy?
Her2/neu overexpression does not appear to predispose to LRR after neoadjuvant doxorubicin-based chemotherapy, mastectomy, and RT.
GLN supplementation inhibited the PI-3K/Akt pathway that is thought to be important in increasing cell survival during tumorigenesis. These results are in agreement with our hypothesis that GLN counteracts the effects of DMBA and blocks carcinogenesis in vivo.